Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
Arrowhead Pharmaceuticals won UK MHRA marketing authorization for REDEMPLO (plozasiran) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronaemia syndrome. NICE separately recommended NHS funding in England and Wales for genetically confirmed FCS under a commercial arrangement, making this a full approval-plus-reimbursement win in the company's first European market. Authorization was based on the Phase 3 PALISADE study (75 patients), where the 25 mg dose significantly reduced median fasting triglycerides vs placebo (p<0.0001) at month 10.
Key figures
- Drug Name
- REDEMPLO (plozasiran)
- Phase Of Trial
- Phase 3
- Trial name
- PALISADE (NCT05089084)
- Recommended dose
- 25 mg
- Trial enrollment
- 75
- Tg reduction p value
- p<0.0001 vs placebo at month 10
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.